These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37715261)

  • 1. Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry.
    Garcia AR; Blanco I; Ramon L; Pérez-Sagredo J; Guerra-Ramos FJ; Martín-Ontiyuelo C; Tura-Ceide O; Pastor-Pérez F; Escribano-Subías P; Barberà JA
    Respir Res; 2023 Sep; 24(1):223. PubMed ID: 37715261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study.
    Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Freire M; Vargas-Hitos JA; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Espinosa G; Colunga-Argüelles D; Ortego-Centeno N; Trapiella-Martínez L; Carbonell-Muñoz C; Pla-Salas X; Perales-Fraile I; Corbella X; Fonollosa-Pla V; Simeón-Aznar CP;
    J Rheumatol; 2020 Jan; 47(1):89-98. PubMed ID: 30770503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy.
    Ruiz G; Yeaw J; Lickert CA; De AP; Wade RL; Pruett J; Drake W
    J Health Econ Outcomes Res; 2018; 5(2):206-219. PubMed ID: 35620777
    [No Abstract]   [Full Text] [Related]  

  • 8. Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors.
    Kane LB; Klings ES
    Treat Respir Med; 2006; 5(4):271-82. PubMed ID: 16808546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase-5 inhibitors in pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
    Turner JM; Russo F; Deprest J; Mol BW; Kumar S
    BJOG; 2022 Oct; 129(11):1817-1831. PubMed ID: 35352868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial.
    Zhang J; Kan J; Wei Y; Zhang C; Yang Z; Gu H; Fan F; Gu H; Wang Q; Xie D; Zhang G; Guo X; Yin Y; Jin B; Zhou H; Yang Z; Wang Z; Xin Y; Zhang C; Meng L; Wang X; Zhao C; Zhang H; Yan X; Chen F; Yao C; Benza RL; Stone GW; Chen SL
    J Heart Lung Transplant; 2023 Aug; 42(8):1140-1151. PubMed ID: 36990173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension.
    Lange TJ
    Herz; 2023 Aug; 48(4):259-265. PubMed ID: 37085727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management and prognosis of HIV-associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry.
    Salvador ML; Rodríguez-Padial L; Soto Abánades C; Cruz Utrilla A; Barberá Mir JA; López-Meseguer M; Segovia Cubero J; Samper GJ; Blanco Vich I; Escribano-Subías P; ;
    J Intern Med; 2022 Jul; 292(1):116-126. PubMed ID: 35184348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Portopulmonary hypertension: prognosis and management in the current treatment era - results from the REHAP registry.
    Lazaro Salvador M; Quezada Loaiza CA; Rodríguez Padial L; Barberá JA; López-Meseguer M; López-Reyes R; Sala-Llinas E; Alcolea S; Blanco I; Escribano-Subías P;
    Intern Med J; 2021 Mar; 51(3):355-365. PubMed ID: 31943676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Effects of ACE Insertion/Deletion and GNB3 C825T Polymorphisms on the Efficacy of PDE-5 Inhibitor in Patients with Pulmonary Hypertension.
    Nishimura R; Tanabe N; Sekine A; Kasai H; Suda R; Kato F; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
    Respiration; 2016; 91(2):132-40. PubMed ID: 26821322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
    Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Colunga-Argüelles D; Argibay A; Marí-Alfonso B; Marín-Ballvé A; Pla-Salas X; Chamorro AJ; Castro-Salomó A; Madroñero-Vuelta AB; Sánchez-García ME; Sáez-Comet L; González-Echávarri C; Ortego-Centeno N; Vargas-Hitos JA; Todolí-Parra JA; Trapiella-Martínez L; Lledó GM; Freire M; Fonollosa-Pla V; Simeón-Aznar CP;
    Rheumatology (Oxford); 2021 Feb; 60(2):872-880. PubMed ID: 32844220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
    Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
    Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial.
    Kan J; Zhang H; Xie D; Wei Y; Zhang J; Zhang C; Yang Z; Gu H; Fan F; Gu H; Wang Q; Zhang G; Guo X; Yin Y; Wang X; Jin B; Zhou H; Yang Z; Wang Z; Xin Y; Zhang C; Meng L; Wang X; Zhao C; Yan X; Chen F; Yao C; Stone GW; Chen SL
    EuroIntervention; 2023 Oct; 19(8):684-694. PubMed ID: 37458100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.